Madrigal Pharmaceuticals Files 8-K on Financials

Ticker: MDGL · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1157601

Sentiment: neutral

Topics: financial-reporting, operations, exhibits

Related Tickers: MDGL

TL;DR

Madrigal Pharma dropped an 8-K on Feb 26th covering financials. Check it out.

AI Summary

Madrigal Pharmaceuticals, Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in West Conshohocken, Pennsylvania.

Why It Matters

This filing provides investors with crucial updates on Madrigal Pharmaceuticals' financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or unusual risks.

Key Numbers

Key Players & Entities

FAQ

What specific financial information is detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details are not provided in the header.

When was Madrigal Pharmaceuticals, Inc. incorporated?

Madrigal Pharmaceuticals, Inc. was incorporated in Delaware.

What is the primary business address of Madrigal Pharmaceuticals?

The principal executive offices are located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania, 19428.

Has Madrigal Pharmaceuticals undergone a name change previously?

Yes, the company was formerly known as SYNTA PHARMACEUTICALS CORP, with a date of name change on August 15, 2001.

What is the telephone number provided for Madrigal Pharmaceuticals?

The registrant's telephone number, including area code, is (267) 824-2827.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding MADRIGAL PHARMACEUTICALS, INC. (MDGL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing